ZI-KL1-1 / Zelluna, National Institutes of Health - LARVOL DELTA

Zelluna Q1 2025 slides highlight TCR-NK manufacturing breakthrough post-merger (Investing.com) - "The first quarter of 2025 was transformative for Zelluna, marked by the completion of its business combination with Ultimovacs ASA on March 3, 2025, accompanied by a private placement of MNOK 51.7...Zelluna’s pipeline consists of three main programs: ZI-MA4-1 targeting MAGE-A4, ZI-KL1-1 targeting KK-LC-1, and ZI-PR-1 targeting PRAME...Zelluna provided an update on the MultiClick Technology and UV1 Program inherited from Ultimovacs....two remaining trials, LUNGVAC and DOVACC, have completed enrollment with topline results expected during 2025....Zelluna outlined several key upcoming milestones that could serve as value inflection points. In the second half of 2025, the company expects to complete preclinical work, begin GMP manufacturing, and submit IND/CTA applications. Initial clinical readouts are anticipated in the first half of 2026."

Clinical data • M&A • Cervical Cancer • Gastric Cancer • Head and Neck Cancer • Non Small Cell Lung Cancer • Ovarian Cancer • Pancreatic Cancer • Sarcoma • Synovial Sarcoma